Skip to content

Statins for Venous Event Reduction in Patients With Venous Thromboembolism

Venous Thromboembolism | Post Thrombotic Syndrome | Blood Clot

The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary embolism is treatment with blood thinners (called anticoagulants).

While treatment of blood clots with blood thinners is effective, some research has shown that adding a statin (medication used to lower cholesterol) may give extra protection. It is thought that statins can improve how cells along the walls of the vein control inflammation, which can prevent new blood clots from forming.

The medication in this study, rosuvastatin, is approved in Canada for use as a cholesterol-lowering medication. The use of rosuvastatin in this study is considered investigational. This means that Health Canada has not approved the use of rosuvastatin as a treatment for blood clots. However, it has been approved for use in this research study.

The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. The investigators also hope to discover if taking a statin reduces damage to your veins. To do this, some of the participants in this study will get rosuvastatin and others will receive a placebo (a substance that looks like the study rosuvastatin but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your blood clot. A placebo is used to make the results of the study more reliable.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

1\. Symptomatic objectively confirmed proximal leg DVT (above the trifurcation of the popliteal vein) and/or PE (segmental or greater) diagnosed in the last 30 days.

Exclusion criteria

1. Unable or unwilling to provide written informed consent;
2. \< 18 years of age;
3. Women of childbearing potential unwilling to use appropriate contraception;
4. Currently prescribed a statin;
5. A known medical history or current diagnosis of any of the following for which statins are indicated in secondary prevention:

1. Diabetes;
2. Abdominal aortic aneurysm;
3. Peripheral arterial disease;
4. Stroke;
5. Transient ischemic attack (TIA);
6. Myocardial infarction (MI);
7. Acute coronary syndromes;
8. Stable/unstable angina;
9. Coronary or other arterial revascularization;
6. Known diagnosis of hypercholesterolemia or dyslipidemia;
7. Contraindication to rosuvastatin;

1. Known hypersensitivity or intolerance to statins;
2. History of muscle disorders or statin-related muscle pain;
3. Known liver disease (active liver disease, e.g. Hepatitis A, B, C, non-alcoholic fatty liver);
4. Chronic kidney disease (creatinine clearance \< 30ml/min);
5. Currently pregnant or breast feeding;
6. Taking cyclosporine;
7. Taking atazanavir/ritonavir;
8. Taking darolutamide;
9. Taking regorafenib;
8. Unstable medical or psychological condition that would interfere with trial participation.

Lieu de l'étude

St. Joseph's Healthcare
St. Joseph's Healthcare
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Niagara Health - St. Catharines Site
Niagara Health - St. Catharines Site
St. Catharines, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Kailee Morrison

McGill Univeristy Health Centre
McGill Univeristy Health Centre
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Foothills Medical Centre
Foothills Medical Centre
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Jill Baxter

Juravinski Hospital
Juravinski Hospital
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Sunnybrook Hospital
Sunnybrook Hospital
Toronto, Ontario
Canada

Contactez l'équipe d'étude

CHU de Quebec-Université Laval
CHU de Quebec-Université Laval
Quebec City, Quebec
Canada

Contactez l'équipe d'étude

Hamilton General Hospital
Hamilton General Hospital
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Hôpital Montfort
Hôpital Montfort
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Jewish General Hospital
Jewish General Hospital
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Queen Elizabeth II Hospital
Queen Elizabeth II Hospital
Halifax, Nova Scotia
Canada

Contactez l'équipe d'étude

The Ottawa Hospital
The Ottawa Hospital
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

University Health Network
University Health Network
Toronto, Ontario
Canada

Contactez l'équipe d'étude

CIUSSS de-l'Ouest-de-l'Ile-de-Montreal -St. Mary's Hospital Center
CIUSSS de-l'Ouest-de-l'Ile-de-Montreal -St. Mary's Hospital Center
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Clinical Research Coordinator

[email protected]
514-345-3511
CHU de Quebec-Université Laval
CHU de Quebec-Université Laval
Québec, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
Ottawa Hospital Research Institute
Participants recherchés
Plus d'informations
ID de l'étude: NCT04319627